COMP <GO>
PBH vs ABBV // GROSS PROFIT MARGIN
Prestige Consumer Healthcare Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: PBH 5
— ABBV 8
▲ GROSS PROFIT MARGIN LEADER: ABBV
LAST: $48.75 (+2.01%) • MKT CAP: $2.31B
gross-margins
54.70%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
gross-margins
70.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PBH VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PBH | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 54.70% | 70.20% | -15.50 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 13.80% | 29.00% | -15.20 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 7.0x | 33.3x | -26.30 | PBH | /valuation <GO> |
| Free Cash Flow Yield | 10.67% | 3.47% | +7.20 | PBH | /fcf-yield <GO> |
| Operating Margin | 28.40% | 24.60% | +3.80 | PBH | /operating-margins <GO> |
| Net Profit Margin | 17.50% | 6.90% | +10.60 | PBH | /net-margins <GO> |
| Revenue Growth (YoY) | -4.30% | 8.60% | -12.90 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.21 | 5.33 | -3.12 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.1 | 65.1 | -10.96 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 11.3x | 113.1x | -101.80 | PBH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.31B | $513.86B | -$511.55B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PBH REV | ABBV REV | PBH GROSS % | ABBV GROSS % | PBH FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.09B | $61.16B | 54.7% | 70.2% | $246.4M | $17.82B |
| FY 2024 | $1.14B | $56.33B | 55.8% | 70.0% | $243.3M | $17.83B |
| FY 2023 | $1.13B | $54.32B | — | — | $248.9M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PBH // BETA —
ABBV // BETA 1.15